Diadema Partners LP Cogent Biosciences, Inc. Transaction History
Diadema Partners LP
- $383 Billion
- Q1 2025
A detailed history of Diadema Partners LP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 392,213 shares of COGT stock, worth $2.4 Million. This represents 0.61% of its overall portfolio holdings.
Number of Shares
392,213
Previous 90,000
335.79%
Holding current value
$2.4 Million
Previous $702 Million
234.67%
% of portfolio
0.61%
Previous 0.3%
Shares
2 transactions
Others Institutions Holding COGT
# of Institutions
196Shares Held
116MCall Options Held
61.9KPut Options Held
223K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$55.6 Million4.6% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY8.96MShares$54.8 Million2.75% of portfolio
-
Commodore Capital LP New York, NY8.89MShares$54.3 Million5.22% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$44.5 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$42.6 Million10.05% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $402M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...